Clinical Trial

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP. Regimen A will evaluate the safety and efficacy of a single study drug, AADvac1, in participants with PSP.
Protocol Amendment History 1 change
critical Enrolling by invitation only 2026-08-13
Trial Details
NCT Number NCT07217665
Lead Sponsor Adam Boxer
Collaborators: National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute, University of Southern California, Massachusetts General Hospital, University of California, San Diego, Alzheimer's Clinical Trials Consortium, Axon Neuroscience SE
Conditions PSP - Progressive Supranuclear Palsy
Enrollment 146 participants
Start Date 2026-07-29
Primary Completion 2030-09-28 (estimated)
Study Completion 2030-09-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-13